Form 4: Atai Life Sciences Director Trades Under 10b5-1 Plan

Atai Life Sciences Director Robert Hershberg executed a Rule 10b5-1 trading plan, involving the exercise of stock options and sale of common stock.

Summary

• Director Robert Hershberg engaged in transactions involving Atai Life Sciences' common stock on July 7, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on April 7, 2026.
• Hershberg exercised stock options, acquiring 48,858 shares at $1.35 per share and an additional 51,142 shares at $1.35 per share.
• Following the option exercises, 100,000 shares of common stock were sold at a weighted average price of $4.96 per share, with individual sale prices ranging from $4.90 to $5.08.
• The total number of common shares beneficially owned by Hershberg after these transactions is 100,000.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves a director selling shares, the transactions were conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns about opportunistic selling.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The stock options exercised were fully vested.
• The sale price of $4.96 per share is significantly higher than the exercise price of $1.35 per share, indicating a profitable transaction for the reporting person.

Negatives

• A significant number of shares (100,000) were sold by a director, which could be interpreted negatively by the market.
• The weighted average sale price of $4.96 is at the lower end of the reported range ($4.90 to $5.08).

Risks

• Potential for negative market perception due to a director selling a substantial number of shares, even if executed under a 10b5-1 plan.
• The specific details of the 10b5-1 plan, such as the duration and specific sale parameters, are not fully disclosed in this filing.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports past transactions.

Management Comments

• The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 7, 2026.
• The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.90 to $5.08.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• The stock option is fully vested.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a director of Atai Life Sciences is a common practice to facilitate planned stock sales while adhering to insider trading regulations, especially in the biopharmaceutical sector where stock price can be volatile.

Stakeholder Impact

• Shareholders: May view the sale of shares by a director with some concern, although the Rule 10b5-1 plan provides a mitigating factor. The profit realized by the director is a positive for their personal financial situation.
• Employees: May see this as a standard executive compensation event, especially given the use of a 10b5-1 plan.
• Creditors: No direct impact is expected from this type of filing.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The company may provide further updates on insider transactions in subsequent filings.

Key Dates

Keywords

Form 4, SEC Filing, Atai Life Sciences, ATAI, Stock Options, Rule 10b5-1, Insider Trading, Beneficial Ownership, Director Transactions, Common Stock